Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Update

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 44,297 shares, a drop of 36.7% from the November 30th total of 69,969 shares. Currently, 2.3% of the shares of the company are short sold. Based on an average trading volume of 68,762 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 68,762 shares, the short-interest ratio is presently 0.6 days. Currently, 2.3% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alaunos Therapeutics in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Alaunos Therapeutics Price Performance

Shares of NASDAQ TCRT opened at $3.23 on Monday. The stock has a market capitalization of $7.49 million, a PE ratio of -1.40 and a beta of -1.29. The business has a fifty day moving average price of $3.26 and a two-hundred day moving average price of $3.15. Alaunos Therapeutics has a fifty-two week low of $1.31 and a fifty-two week high of $6.20.

Alaunos Therapeutics (NASDAQ:TCRT) last released its earnings results on Friday, November 14th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.90) by $4.35.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.